Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Press Releases
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
CommuniquÚs de presse de la sociÚtÚ VIROGATES A/S
01/11NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
2021ViroGates publishes the financial calendar for 2022
AQ
2021ViroGates on positive EMA opinion regarding suPAR-guided anakinra treatment (Video)
AQ
2021ViroGates announces a positive opinion from the CHMP of the EMA for suPAR-guided anakin..
AQ
2021VIROGATES A/S : SuPAR independently predicts severity and length of hospitalisation in pat..
PU
2021ViroGates announces a development, supply and collaboration agreement with Italy-based ..
AQ
2021FRONTIERS IN IMMUNOLOGY PUBLICATION : Soluble Urokinase Plasminogen Activator Receptor (su..
PU
2021ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finali..
AQ
2021NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
2021Interim Report – Q1-Q3, 2021
PU
2021VIROGATES ANNOUNCES ITS INTERIM REPO : Revenue growth of 66% for the first nine months of ..
AQ
2021ViroGates announces a delay in the development and launch of its pipeline product suPAR..
AQ
2021Invitation to ViroGates' Q3 2021 presentation
AQ
2021Elevated preoperative suPAR is a strong and independent risk marker for postoperative c..
PU
2021VIROGATES A/S : announces a new hospital as a clinical routine customer in Greece
AQ
2021VIROGATES A/S : SuPAR is associated with risk for thromboembolic complications and mortali..
PU
2021EVALUATION OF SUPAR LEVELS IN PATIEN : An observational cohort study
PU
2021VIROGATES A/S : SuPAR measured using suPARnostic« TurbiLatex predicts critical illness and..
PU
2021VIROGATES A/S : SAVE-MORE study on the effect of suPARnostic« guided anakinra treatment in..
AQ
2021VIROGATES A/S : notification of transactions by persons discharging managerial responsibil..
AQ
2021SUPAR : An exciting biomarker of systemic chronic inflammation
PU
2021VIROGATES : Eagerly awaiting October
AQ
2021VIROGATES ANNOUNCES ITS HALF-YEAR RE : Increasing clinical revenue and positive topline re..
AQ
2021VIROGATES A/S : SuPAR (cut-off levels ⩽4, 4-6, and ⩾6 ng/mL) predicted the n..
PU
2021VIROGATES A/S : Invitation to ViroGates' Q2 2021 presentation
AQ
2021VIROGATES A/S : SuPAR is a useful biomarker to investigate the link between stressful life..
PU
2021VIROGATES A/S : SuPAR is a valuable tool for predicting the risk of developing severe cons..
PU
2021VIROGATES A/S : notification of transactions by persons discharging managerial responsibil..
AQ
2021VIROGATES A/S : announces CE-IVD approval for suPARnostic« TurbiLatex on the Siemens Healt..
AQ
2021NEW STUDY : suPAR cut-offs for stratification of acute medical patients
PU
2021VIROGATES A/S : General Hospital of Nikaia Agios Panteleimon
PU
2021VIROGATES A/S : ED triage at Sismanoglio General Hospital
PU
2021VIROGATES A/S : announces its first clinical routine customer in Italy
AQ
2021VIROGATES A/S : announces a capital increase in connection with the exercise of warrants
AQ
2021PREPRINT PUBLISHED : suPAR guided early anakinra treatment for COVID-19
PU
2021VIROGATES A/S : reports use of suPAR-guided anakinra treatment improved overall clinical o..
AQ
2021VIROGATES ANNOUNCES ITS INTERIM REPO : Increasing clinical sales
AQ
2021VIROGATES A/S : Resolutions from the Annual General Meeting of ViroGates A/S
AQ
2021VIROGATES A/S : gives notice to convene the Annual General Meeting on 27 April 2021
AQ
2021VIROGATES A/S : Our annual report for 2020 has been published
PU
2021VIROGATES ANNOUNCES ITS ANNUAL REPOR : Growing revenue and customer base - a robust platfo..
AQ
2021VIROGATES A/S : announces CE-IVD approval for suPARnostic« TurbiLatex on the Abbott Alinit..
AQ
2021VIROGATES A/S : announces a new clinical routine customer in Greece
AQ
2021VIROGATES A/S : suPAR en el Complejo Asistencial Universitario de Salamanca
PU
2021VIROGATES A/S : announces clinical routine use in Greece
AQ
2021VIROGATES A/S : Policlínica Nuestra Señora del Rosario is our new clinical routine custome..
PU
2021VIROGATES A/S : announces a new private hospital as clinical routine customer in Spain
AQ
2021VIROGATES A/S : announces initiation of a clinical trial with HISS to clinically validate ..
AQ
2021VIROGATES A/S : announces a delay in the development and launch of its suPARnostic« POC+ p..
AQ
2020VIROGATES A/S : publishes the financial calendar for 2021
AQ
2020VIROGATES A/S : Mikkeli Central Hospital becomes first clinical routine customer in Finlan..
PU
2020VIROGATES A/S : announces receipt of the first order from Mikkeli Central Hospital in Finl..
AQ
2020VÄSTRA HAMNEN : ViroGates - Stronger across the board
AQ
2020VIROGATES A/S : announces its Interim Report for Q3, 2020 - Increasing revenue and two new..
AQ
2020VIROGATES A/S : High suPAR is related to accelerated aging, study in the Journals of Geron..
PU
2020VIROGATES A/S : Resolutions from the Annual General Meeting of ViroGates A/S
AQ
2020VÄSTRA HAMNEN : áViroGates -áSteadily growing customer base
AQ
2020VIROGATES A/S : announces its third clinical routine customer in Spain
AQ
2020VIROGATES A/S : announces its Interim Report for Q2, 2020 - New clinical routine customers..
AQ
2020CORRECTION : ViroGates notice to convene the annual general meeting on 25 August 2020
PU
2020VIROGATES A/S : notice to convene the annual general meeting on 25 August 2020
AQ
2020VIROGATES A/S : announces a capital increase in connection with the exercise of warrants
AQ
2020VIROGATES A/S : suPARnostic«TurbiLatex now CE/IVD approved for the Abbott Architect Chemic..
PU
2020VIROGATES A/S : announces a new clinical routine customer in Spain
AQ
2020VIROGATES A/S : announces CE-IVD approval and launch of suPARnostic« TurbiLatex on the Abb..
AQ
2020VIROGATES A/S : postpones the Annual General Meeting scheduled for 18 June 2020
PU
2020VIROGATES A/S : awarded a 6.6 DKKm EU Horizon 2020 grant for a project to optimize hospita..
AQ
Upcoming event on VIROGATES A/S
03/30/22